WallStreetZenWallStreetZen

NASDAQ: CSBR
Champions Oncology Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their CSBR stock forecasts and price targets.

Forecast return on equity

Is CSBR forecast to generate an efficient return?
Company
N/A
Industry
9.55%
Market
31.36%

Forecast return on assets

Is CSBR forecast to generate an efficient return on assets?
Company
N/A
Industry
9.41%

CSBR revenue forecast

What is CSBR's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$55.7M+13.18%
Avg 2 year Forecast
$62.6M+27.17%
CSBR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CSBR revenue growth forecast

How is CSBR forecast to perform vs Biotechnology companies and vs the US market?
Company
13.18%
Industry
246.57%
Market
12.87%
CSBR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CSBR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CSBR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CSBR$5.06N/AN/A
CUE$1.41$8.00+467.38%Strong Buy
LVTX$2.64$6.00+127.27%Buy
CARM$1.64$7.50+357.32%Strong Buy
ANTX$2.28$6.50+185.09%Buy

Champions Oncology Stock Forecast FAQ

What is CSBR's revenue growth forecast for 2024-2025?

(NASDAQ: CSBR) Champions Oncology's forecast annual revenue growth rate of 13.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 246.57%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.87%.

Champions Oncology's revenue in 2024 is $49,224,000.On average, 1 Wall Street analysts forecast CSBR's revenue for 2024 to be $757,308,760, with the lowest CSBR revenue forecast at $757,308,760, and the highest CSBR revenue forecast at $757,308,760.

In 2025, CSBR is forecast to generate $850,969,814 in revenue, with the lowest revenue forecast at $850,969,814 and the highest revenue forecast at $850,969,814.

If you're new to stock investing, here's how to buy Champions Oncology stock.

What is CSBR's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: CSBR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9.41%.

What is CSBR's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: CSBR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.